GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

By J. Meier. Nature Reviews Endocrinology, 2012

1,256 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. (2014, neutral): “…analogs, like exenatide and lixisenatide, display a marked reduction of GE, which may contribute to short-term effects on food intake, while liraglutide and exenatide, formulated for slow release, have only a minor effect on GE, which then cannot be the mediator of the body weight effects (16, 17).”
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024, background): “49 GLP-1RAs represent a pharmacotherapeutic category of injectable hypoglycemic agents that are sanctioned as adjunctive therapies to diet and exercise for the management of type 2 diabetes mellitus (T2DM) in adult patients and potentially hold promise in addressing other medical conditions.”
GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art (2020, background): “Prandial glycemic excursions Can be reduced with appropriately dosed basal insulin Reduced through deceleration of gastric emptying (short-acting GLP-1 RAs) and the influence on insulin and/or glucagon secretion [31] Short-acting GLP-1 RAs maintain their effect on gastric emptying with continued adm”